iData Insights

Dyslipidemia - Pipeline Review, H2 2015 Now Available at iData Insights

Press Release   •   Jan 30, 2016 12:45 IST

This report provides comprehensive information on the therapeutic development for Dyslipidemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyslipidemia and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Dyslipidemia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Dyslipidemia and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects - A review of the Dyslipidemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Dyslipidemia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Dyslipidemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Dyslipidemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Browse Complete Report with TOC

To Get Sample Copy of Report visit

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 10

Introduction 11

Global Markets Direct Report Coverage 11

Dyslipidemia Overview 12

Therapeutics Development 13

Pipeline Products for Dyslipidemia - Overview 13

Pipeline Products for Dyslipidemia - Comparative Analysis 14

Dyslipidemia - Therapeutics under Development by Companies 15

Dyslipidemia - Therapeutics under Investigation by Universities/Institutes 21

Dyslipidemia - Pipeline Products Glance 22

Late Stage Products 22

Clinical Stage Products 23

Early Stage Products 24

Unknown Stage Products 25

Dyslipidemia - Products under Development by Companies 26

Dyslipidemia - Products under Investigation by Universities/Institutes 34

Dyslipidemia - Companies Involved in Therapeutics Development 35

Acasti Pharma Inc. 35

Allergan Plc 36

Alnylam Pharmaceuticals, Inc. 37

Amgen Inc. 38

Arbutus Biopharma Corporation 39

Arisaph Pharmaceuticals, Inc. 40

Astellas Pharma Inc. 41

AstraZeneca Plc 42

AtheroNova Inc. 43


BCWorld Pharm Co. Ltd. 45

Cadila Pharmaceuticals Ltd. 46

Cardax Pharmaceuticals, Inc. 47

Catabasis Pharmaceuticals, Inc. 48

Cerenis Therapeutics Holding SA 49

Chong Kun Dang Pharmaceutical Corp. 50

CJ HealthCare Corp. 51

Connexios Life Sciences Pvt. Ltd. 52

CymaBay Therapeutics, Inc. 53

Daewoong Pharmaceutical Co., Ltd. 54

Daiichi Sankyo Company, Limited 55

Debiopharm International S.A. 56

Eli Lilly and Company 57

Gemphire Therapeutics Inc. 58

Genfit SA 59

GlaxoSmithKline Plc 60

HanAll Biopharma Co., Ltd. 61

Hanmi Pharmaceuticals, Co. Ltd. 62

Huons Co., Ltd. 63

Hyundai Pharmaceutical Co., Ltd. 64

Innovent Biologics, Inc. 65

IPCA Laboratories Limited 66

Isis Pharmaceuticals, Inc. 67

Jeil Pharmaceutical Co., Ltd. 68

Jenrin Discovery, Inc. 69

JW Pharmaceutical Corporation 70

Kissei Pharmaceutical Co., Ltd. 71

Kotobuki Pharmaceutical Co., Ltd. 72

Kowa Company, Ltd. 73

Kymab Limited 74

LG Life Science LTD. 75

Lipicard Technologies Limited 76

Lotus Pharmaceutical Co., Ltd. 77

Merck & Co., Inc. 78

Nimbus Therapeutics, LLC 79

Nippon Chemiphar Co., Ltd. 80

Pfizer Inc. 81

Pharmena SA 82

Prometheon Pharma, LLC 83

Protalix BioTherapeutics, Inc. 84

Sancilio & Company, Inc. 85

Takeda Pharmaceutical Company Limited 86

Thetis Pharmaceuticals LLC 87

Torrent Pharmaceuticals Limited 88

Viking Therapeutics, Inc. 89

Yuhan Corporation 90

Zydus Cadila Healthcare Limited 91

Dyslipidemia - Therapeutics Assessment 92

Assessment by Monotherapy Products 92

Assessment by Combination Products 93

Assessment by Target 94

Assessment by Mechanism of Action 99

Assessment by Route of Administration 102

Assessment by Molecule Type 104

Drug Profiles 106

(amlodipine besylate + atorvastatin + valsartan) - Drug Profile 106

(amlodipine besylate + rosuvastatin calcium + valsartan) - Drug Profile 107

(atorvastatin calcium + hydroxychloroquine sulfate) - Drug Profile 108

(atorvastatin calcium + losartan potassium) - Drug Profile 109

(atorvastatin calcium + metformin hydrochloride) XR - Drug Profile 110

(candesartan + rosuvastatin calcium) - Drug Profile 111

(ezetimibe + rosuvastatin calcium) - Drug Profile 112

(gemigliptin + rosuvastatin calcium) - Drug Profile 113

(pitavastatin + valsartan) - Drug Profile 114

(rosuvastatin calcium + metformin SR) - Drug Profile 115

4655-K09 - Drug Profile 116

AEM-28 - Drug Profile 117

AEM-2802 - Drug Profile 118

AEM-2814 - Drug Profile 119

AHRO-001 - Drug Profile 120

ALN-AC3 - Drug Profile 122

ALN-ANG - Drug Profile 123

AMG-899 - Drug Profile 124

anacetrapib - Drug Profile 125

ARI-3037MO - Drug Profile 127

AS-1708727 - Drug Profile 128

AZ-12260493 - Drug Profile 129

BCWPC-001 - Drug Profile 130

bezafibrate ER - Drug Profile 131

BH-03004 - Drug Profile 132

BioE-1115 - Drug Profile 133

bococizumab - Drug Profile 134

BSN-272 - Drug Profile 135

C-24 - Drug Profile 136

C-3 - Drug Profile 137

CAT-2000 Series - Drug Profile 138

CAT-2003 - Drug Profile 139

CDR-267F018 - Drug Profile 140

CDX-085 - Drug Profile 141

centatin - Drug Profile 143

CER-209 - Drug Profile 144

CKD-519 - Drug Profile 145

CNX-013B2 - Drug Profile 146

Debio-0930B - Drug Profile 147

DF-461 - Drug Profile 148

DGAT-1 - Drug Profile 149

DPR-212 - Drug Profile 150

DS-8312 - Drug Profile 151

DWJ-1330 - Drug Profile 152

DWJ-1351 - Drug Profile 153

elafibranor - Drug Profile 154

etanercept biosimilar - Drug Profile 157

evolocumab - Drug Profile 158

gemcabene calcium - Drug Profile 161

GSK-2041706 - Drug Profile 162

HCP-1105 - Drug Profile 163

HOB-071 - Drug Profile 164

HU-012 - Drug Profile 165

IBI-306 - Drug Profile 166

icosabutate - Drug Profile 167

ISIS-ANGPTL3LRx - Drug Profile 168

ISIS-ANGPTL3Rx - Drug Profile 169

ISIS-APOCIIILRx - Drug Profile 170

JD-2000 Series - Drug Profile 171

JD-5000 Series - Drug Profile 172

JD-5006 - Drug Profile 173

JD-6000 Series - Drug Profile 174

JLP-1302 - Drug Profile 175

JLP-1401 - Drug Profile 176

K-312 - Drug Profile 177

K-877 - Drug Profile 178

KT-6971 - Drug Profile 180

KTA-439 - Drug Profile 181

KY-1020 - Drug Profile 182

leucine + niacin - Drug Profile 183

LP-071 - Drug Profile 184

LT-5421 - Drug Profile 185

LT-5423 - Drug Profile 186

MAT-9001 - Drug Profile 187

MBX-8025 - Drug Profile 188

MGL-3196 - Drug Profile 190

NC-2400 - Drug Profile 191

ND-630 - Drug Profile 192

ND-654 - Drug Profile 193

NKPL-66 - Drug Profile 195

Read More

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

iData Insights

Tel: 1-866-237-2965


AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future project.